WEBSITE BSE:544687 NSE: HANNAH Inc. Year: 2011 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 11:26
No Notes Added Yet
Hannah Joseph Hospital Ltd is an India based healthcare company that operates a multi specialty hospital and medical services facility in Trivandrum Kerala. The company provides a wide range of medical and surgical services including general medicine surgery obstetrics and gynaecology paediatrics orthopaedics cardiology neurology oncology and critical care. It also offers diagnostic imaging laboratory services emergency care and outpatient consultations. Hannah Joseph Hospital focuses on patient centric care quality clinical outcomes and adopti...Read More
Hannah Joseph Hospital Ltd is an India based healthcare company that operates a multi specialty hospital and medical services facility in Trivandrum Kerala. The company provides a wide range of medical and surgical services including general medicine surgery obstetrics and gynaecology paediatrics orthopaedics cardiology neurology oncology and critical care. It also offers diagnostic imaging laboratory services emergency care and outpatient consultations. Hannah Joseph Hospital focuses on patient centric care quality clinical outcomes and adoption of modern medical technology and practices to serve the healthcare needs of the community. The hospital works with a team of qualified doctors nurses and support staff and caters to both local and referred patients seeking comprehensive healthcare services. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹170 Cr.
Stock P/E 23.6
P/B 1.9
Current Price ₹74.9
Book Value ₹ 40.1
Face Value 10
52W High ₹88.8
Dividend Yield 0%
52W Low ₹ 56
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 58 | 55 | 63 | 78 | |
| Other Income | 0 | 0 | 0 | 0 | |
| Total Income | 58 | 55 | 64 | 78 | |
| Total Expenditure | 40 | 38 | 45 | 57 | |
| Operating Profit | 19 | 17 | 18 | 21 | |
| Interest | 7 | 6 | 5 | 3 | |
| Depreciation | 11 | 9 | 8 | 7 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 1 | 5 | 10 | |
| Provision for Tax | 0 | 0 | 1 | 3 | |
| Profit After Tax | 0 | 1 | 4 | 7 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 1 | 4 | 7 | |
| Adjusted Earnings Per Share | 0.2 | 0.6 | 2.4 | 4.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 24% | 10% | 0% | 0% |
| Operating Profit CAGR | 17% | 3% | 0% | 0% |
| PAT CAGR | 75% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 16% | 10% | 8% | 8% |
| ROCE Average | 18% | 14% | 13% | 13% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 25 | 35 | 46 | 52 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 41 | 30 | 26 | 28 |
| Other Non-Current Liabilities | 7 | 5 | 5 | 4 |
| Total Current Liabilities | 12 | 20 | 12 | 16 |
| Total Liabilities | 84 | 90 | 89 | 99 |
| Fixed Assets | 77 | 71 | 65 | 69 |
| Other Non-Current Assets | 2 | 4 | 3 | 4 |
| Total Current Assets | 5 | 15 | 19 | 23 |
| Total Assets | 84 | 90 | 89 | 99 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 7 | 9 |
| Cash Flow from Operating Activities | 16 | 21 | 8 | 20 |
| Cash Flow from Investing Activities | -3 | -5 | -4 | -13 |
| Cash Flow from Financing Activities | -13 | -10 | -3 | -3 |
| Net Cash Inflow / Outflow | 1 | 5 | 2 | 3 |
| Closing Cash & Cash Equivalent | 1 | 7 | 9 | 12 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.21 | 0.62 | 2.44 | 4.32 |
| CEPS(Rs) | 7.04 | 6.34 | 7.35 | 8.65 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 15.58 | 20.88 | 26.31 | 29.3 |
| Core EBITDA Margin(%) | 31.89 | 30.25 | 28.6 | 26.69 |
| EBIT Margin(%) | 13.34 | 13.64 | 15.99 | 17.82 |
| Pre Tax Margin(%) | 1.12 | 1.86 | 8.43 | 13.35 |
| PAT Margin (%) | 0.58 | 1.85 | 6.41 | 9.3 |
| Cash Profit Margin (%) | 19.28 | 18.96 | 19.37 | 18.64 |
| ROA(%) | 0.4 | 1.16 | 4.53 | 7.64 |
| ROE(%) | 1.37 | 3.43 | 10.42 | 15.53 |
| ROCE(%) | 10.77 | 10 | 13.31 | 17.51 |
| Receivable days | 13.46 | 25.74 | 38.94 | 39.88 |
| Inventory Days | 5.64 | 7.98 | 8.25 | 6.73 |
| Payable days | 106.65 | 129.81 | 105.67 | 85.86 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.97 | 0.96 | 0.62 | 0.5 |
| EV/Core EBITDA(x) | 3.03 | 3.12 | 2.15 | 1.84 |
| Net Sales Growth(%) | 0 | -5.98 | 16.08 | 22.27 |
| EBIT Growth(%) | 0 | -3.86 | 36.14 | 36.26 |
| PAT Growth(%) | 0 | 198.64 | 302.37 | 77.3 |
| EPS Growth(%) | 0 | 190.6 | 293.98 | 77.3 |
| Debt/Equity(x) | 1.9 | 1.26 | 0.71 | 0.69 |
| Current Ratio(x) | 0.43 | 0.73 | 1.55 | 1.47 |
| Quick Ratio(x) | 0.36 | 0.66 | 1.43 | 1.38 |
| Interest Cover(x) | 1.09 | 1.16 | 2.11 | 3.98 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Dec 2025 | Jan 2026 | Mar 2026 |
|---|---|---|---|
| Promoter | 0 | 68.83 | 71.28 |
| FII | 0 | 2.39 | 0.56 |
| DII | 0 | 8.99 | 9.05 |
| Public | 0 | 19.79 | 19.11 |
| Others | 0 | 0 | 0 |
| Total | 0 | 100 | 100 |
| # | Dec 2025 | Jan 2026 | Mar 2026 |
|---|---|---|---|
| Promoter | 0 | 1.56 | 1.62 |
| FII | 0 | 0.05 | 0.01 |
| DII | 0 | 0.2 | 0.21 |
| Public | 0 | 0.45 | 0.43 |
| Others | 0 | 0 | 0 |
| Total | 0 | 2.27 | 2.27 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
